AU2018269462B2 - A pharmaceutical combination for the treatment of a cancer - Google Patents

A pharmaceutical combination for the treatment of a cancer Download PDF

Info

Publication number
AU2018269462B2
AU2018269462B2 AU2018269462A AU2018269462A AU2018269462B2 AU 2018269462 B2 AU2018269462 B2 AU 2018269462B2 AU 2018269462 A AU2018269462 A AU 2018269462A AU 2018269462 A AU2018269462 A AU 2018269462A AU 2018269462 B2 AU2018269462 B2 AU 2018269462B2
Authority
AU
Australia
Prior art keywords
cancer
paclitaxel
compound
abtl0812
abtl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018269462A
Other languages
English (en)
Other versions
AU2018269462A1 (en
Inventor
José ALBERTO ALFÓN CORIAT
Carles DOMÈNECH GARCIA
Miguel FRANCISCO SEGURA GINARD
Jose MIGUEL LIZCANO DE VEGA
Héctor PÉREZ MONTOYO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ability Pharmaceuticals SA
Original Assignee
Ability Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ability Pharmaceuticals SA filed Critical Ability Pharmaceuticals SA
Publication of AU2018269462A1 publication Critical patent/AU2018269462A1/en
Application granted granted Critical
Publication of AU2018269462B2 publication Critical patent/AU2018269462B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018269462A 2017-05-16 2018-05-15 A pharmaceutical combination for the treatment of a cancer Active AU2018269462B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382282 2017-05-16
EP17382282.6 2017-05-16
PCT/EP2018/062554 WO2018210830A1 (en) 2017-05-16 2018-05-15 A pharmaceutical combination for the treatment of a cancer

Publications (2)

Publication Number Publication Date
AU2018269462A1 AU2018269462A1 (en) 2019-11-28
AU2018269462B2 true AU2018269462B2 (en) 2024-04-18

Family

ID=58765794

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018269462A Active AU2018269462B2 (en) 2017-05-16 2018-05-15 A pharmaceutical combination for the treatment of a cancer

Country Status (15)

Country Link
US (3) US11260042B2 (enExample)
EP (2) EP4234035A3 (enExample)
JP (1) JP7208650B2 (enExample)
KR (1) KR102569052B1 (enExample)
CN (2) CN110636842A (enExample)
AU (1) AU2018269462B2 (enExample)
CA (1) CA3063625A1 (enExample)
CL (1) CL2019003288A1 (enExample)
ES (1) ES2955524T3 (enExample)
HU (1) HUE063275T2 (enExample)
IL (1) IL270676B2 (enExample)
MX (1) MX2019013683A (enExample)
PL (1) PL3624786T3 (enExample)
WO (1) WO2018210830A1 (enExample)
ZA (1) ZA201907286B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018269462B2 (en) 2017-05-16 2024-04-18 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer
IL295067A (en) 2020-02-10 2022-09-01 Ability Pharmaceuticals S L Pharmaceutical combination for cancer treatment
CN120733048A (zh) * 2025-08-29 2025-10-03 天津医科大学总医院 一种用于治疗肺鳞癌的药物组合物及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258816A (ja) * 1987-04-16 1988-10-26 Nippon Oil & Fats Co Ltd 抗癌剤組成物
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
AU5928599A (en) * 1999-09-09 2001-04-10 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
GB0011903D0 (en) 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
RU2284818C2 (ru) 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
KR101783817B1 (ko) 2009-05-08 2017-10-23 프로노바 바이오파마 너지 에이에스 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
MY170185A (en) 2011-10-18 2019-07-09 Nestle Sa Composition for use in brain growth and/or cognitive and/or psychomotor development
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
AU2018269462B2 (en) * 2017-05-16 2024-04-18 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer", 14 December 2016 (2016-12-14), XP055409577, Retrieved from the Internet [retrieved on 20170925] *

Also Published As

Publication number Publication date
EP3624786C0 (en) 2023-07-05
US20220257554A1 (en) 2022-08-18
US20240350449A1 (en) 2024-10-24
RU2019135507A (ru) 2021-06-16
US20210154166A1 (en) 2021-05-27
AU2018269462A1 (en) 2019-11-28
EP4234035A2 (en) 2023-08-30
JP7208650B2 (ja) 2023-01-19
WO2018210830A1 (en) 2018-11-22
EP4234035A3 (en) 2023-11-15
KR102569052B1 (ko) 2023-08-22
EP3624786B1 (en) 2023-07-05
BR112019023944A2 (pt) 2020-06-09
CA3063625A1 (en) 2018-11-22
US11260042B2 (en) 2022-03-01
MX2019013683A (es) 2020-01-15
PL3624786T3 (pl) 2023-10-30
IL270676B1 (en) 2024-07-01
JP2020520385A (ja) 2020-07-09
IL270676B2 (en) 2024-11-01
US12053449B2 (en) 2024-08-06
EP3624786A1 (en) 2020-03-25
RU2019135507A3 (enExample) 2021-09-03
KR20200005573A (ko) 2020-01-15
CN119950727A (zh) 2025-05-09
IL270676A (enExample) 2020-01-30
CN110636842A (zh) 2019-12-31
ZA201907286B (en) 2021-01-27
US12280033B2 (en) 2025-04-22
ES2955524T3 (es) 2023-12-04
HUE063275T2 (hu) 2024-01-28
CL2019003288A1 (es) 2020-05-08

Similar Documents

Publication Publication Date Title
Marijon et al. Co-targeting poly (ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells
US12280033B2 (en) Pharmaceutical combination for the treatment of a cancer
Voss et al. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
Ling et al. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
US20100029683A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
US20190255081A1 (en) Combination therapies targeting mitochondria for cancer therapy
Jungwirth et al. KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo
Odhiambo et al. Preclinical evaluation of the ATR inhibitor BAY 1895344 as a radiosensitizer for head and neck squamous cell carcinoma
JP2025525510A (ja) Ｂｃｌ－２阻害剤を含む癌併用療法
HK40098371A (en) A pharmaceutical combination for the treatment of a cancer
RU2801665C2 (ru) Фармацевтическая комбинация для лечения рака
EP4103170B1 (en) A pharmaceutical combination for the treatment of a cancer
JP2020528418A (ja) ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
EP3197463A1 (en) Antitumor activity of multi-kinase inhibitors in colorectal cancer
JP2014513698A (ja) がん治療保護のためのヒ素の使用
HK40120326A (en) A pharmaceutical combination for the treatment of a cancer
Chatterji et al. Microtubules as Anti-Cancer Drug Targets
Reck et al. C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)
EA052727B1 (ru) Фармацевтическая комбинация для лечения рака
George et al. HORMONE THERAPY
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1202423B (en) Combination therapy with a topoisomerase inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)